US9951043 — Therapeutic compounds
Method of Use · Assigned to Gilead Sciences Inc · Expires 2034-02-28 · 8y remaining
What this patent protects
This patent discloses compounds, pharmaceutical compositions, and methods for treating a Retroviridae viral infection, including HIV.
USPTO Abstract
Compounds of formula (I) or salts thereof are disclosed. Also disclosed are pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.
Drugs covered by this patent
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-3507 |
— | lenacapavir-sodium |
U-4190 |
— | lenacapavir-sodium |
U-3507 |
— | lenacapavir-sodium |
U-4190 |
— | lenacapavir-sodium |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.